Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Leuk Lymphoma. 2009 May;50(5):694-702. doi: 10.1080/10428190902866732.

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.

Author information

  • 1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA. jacobp_laubach@dfci.harvard.edu

Erratum in

  • Leuk Lymphoma. 2009 Jul;50(7):1235.

Abstract

Rapid development of the small molecule proteasome inhibitor bortezomib has yielded important clinical benefit for patients with multiple myeloma. Early phase clinical trials suggest the agent has similar efficacy in Waldenströms Macroglobulinemia. Optimization of bortezomib-based therapy, though, requires an understanding of the various challenges associated with use of the drug. This review highlights the rationale for bortezomib therapy in patients with multiple myeloma and Waldenströms Macroglobulinemia, mechanisms of bortezomib resistance, important therapy-related side effects, and new directions for the use of proteasome inhibitors in these disorders.

PMID:
19452315
[PubMed - indexed for MEDLINE]
PMCID:
PMC3133638
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare Icon for PubMed Central
    Loading ...
    Write to the Help Desk